Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 306

Sort by

Sort Order Select

Journal Articles

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Blood (2024) 144 (23): 2432–2438.

https://doi.org/10.1182/blood.2024024995

Published: 2024

Includes: Supplemental data

Journal Articles

Observational, Retrospective and Multicenter Analysis of Spanish CML Group , in Patients with Chronic Myeloid Leukemia in Treatment-Free Remission after Discontinuation of Bosutinib

Gonzalo Maortua Langdon, Raquel De Paz, Pilar Giraldo, Blanca Xicoy, Joaquin Martinez Lopez, Guiomar Bautista Carrascosa, Jose Maria Alonso Alonso, Maria Soledad Noya Pereira, Magdalena Sierra Pacho, Raul Perez Lopez, Silvana Daniela Saavedra Gerosa, Valle Gomez G De Soria, Natalia De Las Heras, Valentín García Gutiérrez, Sr.

Blood (2024) 144 (Supplement 1): 6604.

https://doi.org/10.1182/blood-2024-208460

Published: 2024

Journal Articles

Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)

Blood (2024) 144 (Supplement 1): 3497.

https://doi.org/10.1182/blood-2024-194695

Published: 2024

Journal Articles

Real-World Evidence of First-Line Therapy in Non-Transplant Eligible Multiple Myeloma Patients: Insights from the Cimma Study

Maria-Victoria Mateos, Fernando Escalante, Natalia Marin Huarte, Angela Garcia Garcia-Porrero, Miguel Jesús Villanueva Forero, Rafael Rios Tamayo, Antonia Sampol Mayol, Eugenio Gimenez, Jose-Angel Hernandez Rivas, Savana Research Group, Joaquín Martínez-Lopez

Blood (2024) 144 (Supplement 1): 7878.

https://doi.org/10.1182/blood-2024-206018

Published: 2024

Journal Articles

GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation

Blood (2024) 144 (Supplement 1): 678.

https://doi.org/10.1182/blood-2024-203170

Published: 2024

Journal Articles

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Blood (2024) 144 (Supplement 1): 677.

https://doi.org/10.1182/blood-2024-198403

Published: 2024

Journal Articles

CRISPR/Cas9 Multi-Editing Enhances CAR NK Cells Therapeutic Potential Against Multiple Myeloma

Blood (2024) 144 (Supplement 1): 3442.

https://doi.org/10.1182/blood-2024-207942

Published: 2024

Journal Articles

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Blood (2024) 144 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2024-201730

Published: 2024

Journal Articles

Retrospective Analysis of Spanish Real-World Data Investigating First Line Treatment Patterns in a Representative Sample of Chronic Lymphocytic Leukemia Patients

Zuzana Dostalova, Kai Strobel, Tycho Baumann, Fatima Miras, Joaquín Martínez-Lopez, José Antonio Garcia Vela, Stefan Schilling, Markus Rückert

Blood (2024) 144 (Supplement 1): 7804.

https://doi.org/10.1182/blood-2024-202047

Published: 2024

Journal Articles

Epigenetic Modifications As a Mechanism of Resistance to BCMA-Directed Immunotherapies in Multiple Myeloma: Insights from Multi-Omic Profiling

Larissa Haertle, Natalia Buenache Cuenda, Isabel Espejo Diaz, Paula Lázaro Del Campo, Andres Arroyo-Barea, Leonie Rieger, Juan Manuel Rosa-Rosa, Rafael Alonso Fernandez, Nieves Lopez, José Sanchez-Pina, Almudena García-Ortiz, Antonio Valeri, Santiago Barrio, Fatima Al-Shahrour, Florian Bassermann, Joaquin Martínez-López, Tomas Di Domenico

Blood (2024) 144 (Supplement 1): 5794.

https://doi.org/10.1182/blood-2024-198117

Published: 2024

Journal Articles

Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis

Blood (2024) 144 (Supplement 1): 489.

https://doi.org/10.1182/blood-2024-210198

Published: 2024

Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Isatuximab, Carfilzomib and Dexamethasone in the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Blood (2024) 144 (Supplement 1): 7088.

https://doi.org/10.1182/blood-2024-205189

Published: 2024

Journal Articles

Transcriptional Effects of Cytarabine Based Regimens in Patients with Acute Myeloid Leukemia By RNA-Seq Analysis

Alba Mora, Noemi Álvarez, Rafael Colmenares, Maria Luz Morales, Roberto Garcia-Vicente, Gonzalo Carreño, Inmaculada Rapado, Joaquín Martínez-Lopez, María Linares, Juan Manuel Rosa-Rosa, Rosa Ayala

Blood (2024) 144 (Supplement 1): 6150.

https://doi.org/10.1182/blood-2024-210005

Published: 2024

Journal Articles

Minimal Residual Disease Measured after Treatment with Bispecifics in Relapsed Multiple Myeloma: Experience from an Academic Medical Center

Alberto Blanco, Ajai Chari, Thomas G Martin, Shagun Arora, Alfred Chung, Anupama Deepa Kumar, Nina Shah, Sandy W. Wong, Hiroyuki Takamatsu, Joaquin Martínez-López, Jeffrey Lee Wolf

Blood (2024) 144 (Supplement 1): 7020.

https://doi.org/10.1182/blood-2024-203768

Published: 2024

Journal Articles

Artificial Intelligence Models for Risk Stratification and Prognosis in AML-NOS

Álvaro López-Caro, Ana Mendoza, Miguel Gómez-Álvarez, Marta Hidalgo Soto, Adriana Oñós Clausell, Sandra Rodríguez San Antolín, David Bermejo-Peláez, Nuria Díez Navarro, David Brau Queralt, Maria Postigo Camps, Rafael Colmenares Gil, Maria Jesus Ledesma-Carbayo, María Linares, Julia Montoro, Celina Benavente Cuesta, Miguel Luengo-Oroz, Joaquin Martínez-López

Blood (2024) 144 (Supplement 1): 7509.

https://doi.org/10.1182/blood-2024-207555

Published: 2024

Journal Articles

Clinical Utility of Ctdna Detection By NGS for Diagnosis of CNS Lymphoma

Ana Jiménez Ubieto, Alejandro Martín-Muñoz, Ricardo Errazquin, Yanira Ruiz-Heredia, Laura Rufián, Margarita Rodríguez, Esther Parra, Tycho Baumann, Antonia Rodriguez Izquierdo, Maria Teresa Cedena Romero, Joaquin Martínez-López, Rosa Ayala, Inmaculada Rapado

Blood (2024) 144 (Supplement 1): 6227.

https://doi.org/10.1182/blood-2024-207390

Published: 2024

Journal Articles

Potential Utility of Ctdna to Detect False Positive PET/CT in the Evaluation of Lymphoma Response

Alejandro Martín-Muñoz, Ana Jiménez Ubieto, Yanira Ruiz-Heredia, Laura Rufián, Margarita Rodríguez, Tycho Baumann, Antonia Rodriguez Izquierdo, Maria Poza Santaella, Daniel Gil Alos, Pilar Sarandeses, Enrique Revilla, Gloria Figaredo, Ricardo Errazquin, Inmaculada Rapado, Rosa Ayala, Santiago Barrio, Joaquin Martínez-López

Blood (2024) 144 (Supplement 1): 6204.

https://doi.org/10.1182/blood-2024-206966

Published: 2024

Journal Articles

Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Blood (2024) 144 (Supplement 1): 3414.

https://doi.org/10.1182/blood-2024-205005

Published: 2024

Journal Articles

Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Blood (2024) 144 (Supplement 1): 3374.

https://doi.org/10.1182/blood-2024-205453

Published: 2024

Journal Articles

Leveraging AI for Predicting Genetic Alterations in Multiple Myeloma through Morphological Analysis of Bone Marrow Aspirates

Blood (2024) 144 (Supplement 1): 2230.

https://doi.org/10.1182/blood-2024-207126

Published: 2024

NARROW

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Observational, Retrospective and Multicenter Analysis of Spanish CML Group , in Patients with Chronic Myeloid Leukemia in Treatment-Free Remission after Discontinuation of Bosutinib

Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)

Real-World Evidence of First-Line Therapy in Non-Transplant Eligible Multiple Myeloma Patients: Insights from the Cimma Study

GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

CRISPR/Cas9 Multi-Editing Enhances CAR NK Cells Therapeutic Potential Against Multiple Myeloma

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Retrospective Analysis of Spanish Real-World Data Investigating First Line Treatment Patterns in a Representative Sample of Chronic Lymphocytic Leukemia Patients

Epigenetic Modifications As a Mechanism of Resistance to BCMA-Directed Immunotherapies in Multiple Myeloma: Insights from Multi-Omic Profiling

Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Isatuximab, Carfilzomib and Dexamethasone in the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Transcriptional Effects of Cytarabine Based Regimens in Patients with Acute Myeloid Leukemia By RNA-Seq Analysis

Minimal Residual Disease Measured after Treatment with Bispecifics in Relapsed Multiple Myeloma: Experience from an Academic Medical Center

Artificial Intelligence Models for Risk Stratification and Prognosis in AML-NOS

Clinical Utility of Ctdna Detection By NGS for Diagnosis of CNS Lymphoma

Potential Utility of Ctdna to Detect False Positive PET/CT in the Evaluation of Lymphoma Response

Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Leveraging AI for Predicting Genetic Alterations in Multiple Myeloma through Morphological Analysis of Bone Marrow Aspirates

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only